A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

IRB/UVA Tracking #
21472
Contact
Gracie Hockenberry
Contact Email
Contact Phone
1.434.297.7784
Phase
III
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL
Ages
Adult